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Differential DNA methylation of 
potassium channel KCa3.1 and 
immune signalling pathways is 
associated with infant immune 
responses following BCG 
vaccination
Mateusz Hasso-Agopsowicz  1, Thomas J. Scriba2, Willem A. Hanekom2, Hazel M. Dockrell1 & 
Steven G. Smith1
Bacillus Calmette–Guérin (BCG) is the only licensed vaccine for tuberculosis (TB) and induces highly 
variable protection against pulmonary disease in different countries. We hypothesised that DNA 
methylation is one of the molecular mechanisms driving variability in BCG-induced immune responses. 
DNA methylation in peripheral blood mononuclear cells (PBMC) from BCG vaccinated infants was 
measured and comparisons made between low and high BCG-specific cytokine responders. We found 
318 genes and 67 pathways with distinct patterns of DNA methylation, including immune pathways, 
e.g. for T cell activation, that are known to directly affect immune responses. We also highlight 
signalling pathways that could indirectly affect the BCG-induced immune response: potassium and 
calcium channel, muscarinic acetylcholine receptor, G Protein coupled receptor (GPCR), glutamate 
signalling and WNT pathways. This study suggests that in addition to immune pathways, cellular 
processes drive vaccine-induced immune responses. Our results highlight mechanisms that require 
consideration when designing new TB vaccines.
Mycobacterium bovis Bacillus Calmette–Guérin (BCG) is the only licensed vaccine against tuberculosis (TB). 
BCG protects against severe childhood cases of miliary TB and tuberculous meningitis1. However, the protection 
afforded by the vaccine against pulmonary TB varies across geographical regions with studies reporting vaccine 
efficacy ranging from 0% in India2 to 80% in the United Kingdom (UK)3. Reasons for these variations remain 
unknown. Possible explanations include comorbidities4, pre-exposure to environmental mycobacteria5, and 
genetics6. Previous studies in Malawi7, The Gambia8, Indonesia9 and the UK8,10 have shown disparate immune 
responses across these populations, with a dominant production of IFNγ in the UK and greater production of T 
helper (Th)2 cytokines in Malawi and The Gambia10. Multiple efforts are being undertaken to identify correlates 
of protection following BCG vaccination11,12. The importance of IFNγ has been highlighted in numerous stud-
ies8,13–16, however, the Th1 boosting candidate TB vaccine MVA85A (Modified Vaccinia virus Ankara expressing 
Ag85A from M. tuberculosis) failed to improve on protection afforded by BCG in vaccinated infants17; a large 
South African study did not find that BCG specific Th1 response correlated with risk of TB disease18; however 
further analysis of the MVA85A clinical trial showed that the frequencies of cells producing BCG-specific IFNγ 
was associated with a reduced risk of developing disease16.
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Another unknown factor in the immune response to the BCG vaccine is the molecular mechanism that drives 
these immune responses. Recent studies highlight the role of transcriptomics19–21 as means of identifying the key 
mechanisms and the importance of measuring RNA profiles in vaccine trials. Epigenetics, a mechanism known 
to play a role in regulation of gene expression, is another mechanism of growing importance. Specifically, DNA 
methylation of CpG dinucleotides in mammals is known to regulate gene expression and subsequent protein 
production22,23. In-vitro methylation of herpes thymidine kinase (tk) genes resulted in in-vivo downregulation 
of gene expression24 and methylation of the O6-methylguanine-DNA-methyltransferase (MGMT) gene was neg-
atively correlated with its protein concentration in humans25. In the context of immune responses, two recent 
studies have examined the role of epigenetic regulation, gene expression and protein production in responses to 
Hepatitis B26 and Influenza27 vaccines. Several differentially methylated genes were found between low and high 
immune responders to Hep B vaccine and DNA methylation was correlated with gene expression and protein 
levels for multiple genes following influenza vaccination. Lastly, recent evidence shows that DNA methylation of 
macrophages is correlated with anti-mycobacterial activity in BCG vaccinated participants28.
We have examined whether the DNA methylation profile of peripheral blood mononuclear cells (PBMC) in 
BCG vaccinated infants is associated with the magnitude of BCG specific immune responses. We found novel 
pathways and genes that were differentially methylated between high and low BCG responders amongst South 
African infants who received BCG vaccination at birth. This knowledge will allow us to understand molecular 
mechanisms that drive vaccine-induced immune responses, paving the way to design better and more effective 
TB vaccines.
Results
Sample collection and processing. We used 60 archived frozen PBMC samples from a previous study18. 
36.7% were female, 83.3% Cape Mixed Ancestry, 13.3% Black African and 3.3% Asian. All participants received 
the Japanese BCG vaccine at birth and their blood was collected at 10 weeks post vaccination.
An increase in cytokine production after BCG stimulation is not correlated with cell phenotype. 
To investigate the magnitude of immune responses to the BCG vaccine, we measured the cytokine production 
after stimulation with BCG (SSI strain, 1.2 × 106 organisms/ml) or Staphylococcus Enterotoxin B (SEB) using an 
intracellular cytokine staining (ICS) assay. We looked at cytokine responses in the PBMC population (see gating 
strategy in Fig. 1A). There was a consistent increase in the production of all cytokines after BCG stimulation and 
IFNγ, TNFα, IL2 but not IL8 and IL4/5/13 after SEB stimulation (Fig. 1B). We examined whether the observed 
magnitude of immune responses was due to changes in T cell frequency and conducted a Spearman correlation 
analysis of frequencies of IFNγ-expressing cells following BCG stimulation with other immune parameters. The 
frequencies of BCG-specific IFNγ cells (hereafter called IFNγ BCG) were correlated with IL4/5/13, IL2 and IL8 
secreted following stimulation with BCG but not with any T cell population measured (Table S1). This indicates 
that in this assay, the BCG induced IFNγ production is not correlated with T cell and lymphocyte composition. 
All samples were stratified based on their IFNγ BCG production and 15 highest (IFNγ Low) and 15 lowest (IFNγ 
High) IFNγ BCG producers were selected for the analysis of DNA methylation (Fig. 1C).
Differential methylation of 318 genes between low and high BCG cytokine respondents. A 
total of 30 samples were selected for the DNA methylation analysis. These were stratified based on their BCG spe-
cific immune responses forming low vs. high groups for five cytokines: IFNγ; IL4/5/13; IL2; TNFα; and IL8. For 
each cytokine, DNA methylation of low responders was compared to high responders using logistic regression 
with a minimum difference in methylation of 5%. The analysis showed several probes to be differentially meth-
ylated between low and high groups of: IFNγ (70), IL4/5/13 (108), IL2 (50), TNFα (146), and IL8 (122) (Fig. 2). 
A gene feature report highlighted 318 genes (Table 1) that span the differentially methylated probes. Several 
novel genes of which levels of methylation can indirectly affect the magnitude of BCG immune responses were 
identified. Notably, the ZFP57 gene was found to be differentially methylated in all cytokine low and high groups 
comparisons. ZFP57 is a transcriptional regulator of gene imprinting and it acts by controlling DNA methylation 
during the earliest stages of multicellular development29,30. Another gene candidate KCa3.1 is a protein that forms 
the voltage-independent potassium channel and was found to be differentially methylated across 4 cytokine low 
and high groups (IFNγ, IL2, IL4/5/13 and IL8). Kca3.1 regulates calcium influx and can influence TH1 and TH2 
development31. We also found ERICH-1 to be differentially methylated across cytokine low and high groups. 
ERICH-1 encodes the a glutamate rich 1 protein and glutamate is known to regulate Ca2+ and K+ efflux thereby 
affecting T cell activation32.
Hierarchical cluster analysis reveals clusters of differentially methylated genes. We conducted a 
t-distributed stochastic neighbour embedding (tSNE) analysis of gene methylation for the 30 examined samples, 
however this did not show a clear separation of IFNγ low and IFNγ high nor the other cytokine low and high 
groups (data not shown). This indicates subtle differences in DNA methylation between cytokine low and high 
groups, suggesting that there might also be other mechanisms that drive immune responses to the BCG vaccine. 
We then proceeded with a hierarchical cluster analysis of the differentially methylated probes when stratified 
by cytokine respondents. We saw visible differences in cluster formation for all the cytokine groups measured 
(Fig. 3).
Differentially methylated genes are part of immune and cellular processes pathways. We 
examined biological functions of the differentially methylated genes for all the cytokines using the Panther 
Pathway Analysis (PPA). Differentially methylated genes are included in 67 pathways that are involved in multi-
ple biological processes including immune functions (2.8%), metabolic (20.8%) and cellular (25.3%) processes 
and other processes (Table 2). Several pathways of the immune system could explain the polarisation of cytokine 
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Figure 1. The immune response to the BCG vaccine was used to select samples for analysis. (A) The FACS 
gating strategy used to measure all immune responses. Singlet cells and CD3+ populations were chosen 
to measure intracellular cytokine responses as well as phenotypic markers such as CD3+, CD3+CD4+, 
CD3+CD8+, CD3+CD4+CCR7+, CD3+CD4+CD45RO+. (B) The magnitude of immune responses of PBMCs 
after 12 hours stimulation with BCG and SEB (% of PBMCs). Each column represents one donor sample. 
Stimulated samples were compared to non-stimulated with Wilcoxon paired t test. N = 60; ns = not significant; 
*p < 0.05; ****p < 0.0001 (C) A magnitude of IFNγ BCG responses when stratified by origin (CD3+ 
population). Fifteen lowest (non-responders) and fifteen highest (responders) IFNγ BCG producers (red) were 
selected for the DNA methylation analysis. Samples coloured in grey were not selected. N = 60.
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responses. Notably, T cell activation, interferon gamma signalling, interleukin and JAK/STAT signalling pathways 
were all involved in the regulation of cytokine responses. B cell activation, TGF-beta and chemokine and cytokine 
mediated inflammation were also highlighted as pathways containing genes that were differentially methylated. 
A large proportion of highlighted pathways regulate cellular and metabolic processes. We found differentially 
Figure 2. A scatter plot of all probes of which methylation was compared between a high and low cytokine 
responder group. Each dot represents a probe of which % methylation is measured in a high cytokine group 
(X axis) and low cytokine group (Y axis). Red dots represent probes which are significantly differentially 
methylated. BCG specific low and high cytokine groups that were compared included: IFNγ (A), IL2 (B), IL8 
(C), IL4/5/13 (D), and TNFα (E).
www.nature.com/scientificreports/
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methylated genes that are part of the G-protein signalling pathways, which are known to regulate T cell migra-
tion and activation33. We also found 6 differentially methylated genes in the Wnt pathway, which is known to 
regulate IL12 signalling in antigen presenting cells (APCs)34. Lastly, we highlight the muscarinic acetylcholine 
Name of Cytokine Pairs
Total Number of Differentially 
Methylated Genes Name of Genes
IFNγ IL2 IL4/5/13 IL8 TNFα 1 ZFP57
IFNγ IL2 IL4/5/13 IL8 2 PTPRN2 KCNN4
IFNγ IL2 IL4/5/13 TNFα 4 ERICH1 GPR124 RP5-1029F21.3 COLEC11
IL2 IL4/5/13 IL8 TNFα 2 CTC-281F24.1 MIR4520-1
IFNγ IL2 IL4/5/13 5 RP11-609L3.1 ZMIZ1 AURKC NEURL1B SEPT7P3
IFNγ IL2 TNFα 1 DNAH1
IFNγ IL4/5/13 IL8 1 AZU1
IFNγ IL4/5/13 TNFα 3 LMTK3 LY6K ANO8
IL2 IL8 TNFα 1 CRYGEP
IL2 IL4/5/13 TNFα 1 DTX1
IL4/5/13 IL8 TNFα 2 EHBP1L1 SIPA1
IFNγ IL2 2 PRSS36 MVB12B
IFNγ IL8 1 GCSAML
IFNγ IL4/5/13 17
TTN DEAF1 CARS2 RP11-108K14.12 HELZ2 RGS3 COL1A1 MTHFR 
GRK1 DUSP15 CYP2E1 FIP1L1 LPIN1 TTN-AS1 C1orf167 FBXO41 
CMTM7
IFNγ TNFα 1 LINC00539
IL2 IL8 1 HCN2
IL2 IL4/5/13 3 PDIA3P2 CATSPER2 KCNAB1
IL2 TNFα 2 PROSER3 MAN1C1
IL8 TNFα 3 CUX1 PLEC SLC43A2
IL4/5/13 TNFα 9 PKNOX2 HNRNPH1 AC010907.2 RP11-687M24.8 MAST4 LHX6 ADARB2 AC096649.3 NLGN2
IFNγ 13 MED15P5 NTM CTD-3080P12.3 PIAS4 SPG7 TIMP2 CAMSAP3 SOGA3 CD9 MALRD1 PXDN NTNG2 RP11-599J14.2
IL2 15
RP4-724E13.2 TGFBR3 RP11-452L6.8 COX6A2 CARD11 NINJ2 
SNRPN MAP1LC3BP1 RP11-218M22.1 C20orf96 ANK1 FANCC 
MEGF6 RP4-559A3.7 LEFTY1
IL8 88
RN7SL646P FAM222B ZFP41 PBX4 LINC01169 KCNQ1OT1 TRPV2 
EDARADD UMODL1-AS1 DTNB bP-21264C1.2 RP11-216L13.18 
KIAA1161 CDH23 ZNF473 LINC01266 COL23A1 AC011850.2 
FLJ26850 RP11-394I13.3 LINC00467 SOX10 MSL3P1 AC018688.1 
HIST1H3E FAM217B 5_8S_rRNA RNMTL1 RAI1 RELT LRRC24 
NFATC1 UNC93B1 ZNF790-AS1 EMC9 ITPR1 POU5F1 EGOT 
UMODL1 MIR4508 AC005481.5 VOPP1 AC005538.3 ATP8B3 
POLR2F MIR6820 SDK1 MIR138-2 FRRS1 MIR6813 WDR60 COL5A1 
CTD-2126E3.3 THSD4 OPCML TMPRSS12 RABL6 RP11-133L14.5 
PROSER2-AS1 PIK3R2 PRSS21 RYR1 CLEC9A CTD-2269E23.4 
MAN2B1 ARHGEF10 GLI4 RP11-497G19.1 ATG16L2 LZTS3 WDR20 
SH3GL1 EXD3 AMOTL2 LRRC14 MROH1 CTD-2192J16.22 TARID 
CFD TNFRSF11A MMP17 RGS19 KCNQ1 C8orf82 RNF165 LOXL1 
LINC01312 SYCP2
IL4/5/13 41
TPM4P1 GNAL AC131097.4 RP11-244F12.1 RP11-867G23.12 NBPF13P 
RNVU1-8 RIMBP2 LINC01237 ZNF718 RP11-680G24.4 TAF1C TBCE 
PHACTR3 RP11-662M24.2 RP11-452D2.2 RP11-545A16.3 HLA-DRB9 
PRDM15 KCNN3 PRDM16 DRAXIN ARID3A SNRNP27 COL18A1 
RP11-1260E13.1 RPH3AL RP3-522J7.6 AP001347.6 LRRC37A6P 
PRDM7 MYBPC2 PNPLA6 AC147651.1 PDXDC1 SRC NYAP2 
ADAMTS12 ANKRD20A18P C5orf17 RIN1
TNFα 98
GABRB3 MKRN3 PRKAR1B PAX8-AS1 FAM189A1 RNA5-8S5 ACOT2 
WT1 ACVR1B LINC00839 AOX3P PRDM8 LDLRAD2 CHCHD3 
FBXO16 PEBP4 MARK4 CTU1 HLA-DPA1 ATP5J2 RPL13A MEST 
RASAL2 PRAM1 PRKCQ GNAI2 RP11-127L20.3 RP11-726G23.10 
BRSK1 BCAN CROCC GABRA5 LINC00887 PTCD1 SDF4 FNDC3B 
RPL13P12 CYGB NCOR2 CLIP2 GALNT9 BCR AOX2P OPRL1 RP11-
377G16.2 FLT3LG CTD-3148I10.9 CPT1A RP11-54O7.17 RPS6KA4 
RP11-284F21.7 PIGQ RP11-492E3.2 PRCD AC093609.1 HLA-DPB1 
SEMA6B CH507-513H4.1 UHRF1 CTD-3148I10.15 SEMA3B ZNF331 
GEMIN7 MPPED1 ERICH1-AS1 RP5-906A24.1 PPAPDC3 MGRN1 
ZNF395 FLT4 ITPRIP RP11-426C22.5 KAZN MST1L PSPN ITFG2 
ARL5C RP11-137H2.4 FBXW4P1 PAX8 ALKBH7 C17orf98 RBM19 
NOS3 CCNYL2 RP11-273G15.2 HTRA4 RP11-231D20.2 RP11-65I12.1 
SCARF1 ITGAX RP11-230C9.1 PPP1R37 RP11-56P9.10 OSBPL5 
ATP5J2-PTCD1 CBFA2T3 PLEKHA2
Table 1. A summary of all genes that were differentially methylated across all low and high cytokine groups. 
Each row shows single or multiple genes that were differentially methylated across one or multiple cytokine 
groups. n = 30.
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receptor signalling pathway (mAChRs), which can mediate cytokine production35. By regulating the immune sig-
nalling and cellular processes these pathways can directly and indirectly affect the magnitude of the BCG induced 
immune response that is observed in our samples.
Discussion
BCG vaccination induces variable immunity across populations36,37 translating to an inconsistent protection 
against pulmonary tuberculosis1. This study aimed to answer whether epigenetic modifications, specifically DNA 
methylation, could be one of the molecular mechanisms that drive the observed disparate immune responses.
We first measured the magnitude of immune responses induced after the BCG vaccination. We chose to 
include all cells in the PBMC population as the DNA used for the methylation analysis was extracted from match-
ing vials of PBMC. Similar to the previous study18, we saw an increase of all the measured cytokines following 
BCG stimulation in vitro. The magnitude of immune responses for IFNγ ranged from 0% to 2.61% measured as 
the frequency of cytokine producing PBMCs. As expected, BCG and SEB stimulation decreased the expression 
of CD3 protein and had no effect on the expression of CD4 and CD8 proteins (data not shown) and SEB, an 
inflammatory superantigen38, failed to increase the production of TH2 cytokines and IL8. CD4+ and CD8+ T 
cells are known to be the main producers of IFNγ39, however, we saw that none of the T cell phenotypes measured 
correlated with levels of BCG induced IFNγ (Table S1). This indicates that the magnitude of immune responses is 
independent of cellular T cell composition and is likely driven by molecular mechanisms within individual cells. 
The frequencies of BCG-induced IFNγ had a strong positive correlation with IL2 and IL4/5/13, and a weak neg-
ative correlation with IL8. IL2 is known to activate T cells, which are one of the main IFNγ producers40, and the 
BCG vaccine was shown to previously induce both TH1 and TH2 cytokines7,9. We cannot exclude that changes 
in cell numbers of Natural Killer (NK) cells and monocytes between groups could explain observed differences 
in cytokine levels. This could be addressed by analysing DNA methylation patterns in purified cell populations, 
which due to a limited sample size was beyond the scope of the project.
Having measured the immune responses and selected samples for further analysis, we measured DNA meth-
ylation and stratified samples by high and low cytokine responses. We found probes that were differentially meth-
ylated between high and low cytokine responders and identified the 318 corresponding genes. Interestingly, genes 
that were differentially methylated in many of the cytokine groups were involved in potassium, calcium and 
neurotransmitter signalling.
KCNN4 or Kca3.1, Potassium Calcium-Activated Channel Subfamily N Member 4, was found to be 
differentially methylated in IFNγ, IL2, IL4/5/13, and IL8 high and low groups. The Kca3.1 channel is a 
voltage-independent potassium channel, which is activated by an increase in intracellular calcium, resulting in 
membrane hyperpolarization and continuous calcium influx31. Calcium regulates multiple cellular processes. 
A prolonged contact between a CD4+ T cell and an antigen presenting cell (APC) results in an increase in 
intracellular Ca2+ levels. The main sources of Ca2+ in T cells are store-operated calcium channels (SOCE) and 
calcium-release-activated calcium (CRAC)41–44. A SOCE and CRAC dependent release of calcium inside a CD4+ 
T cells changes gene expression, and thus cytokine production, drives the differentiation of naïve T cells to TH1 or 
TH2 cells, and the development of immature T cells41. A strong Ca2+ signal favours TH1 differentiation45 whereas 
weak Ca2+ release skews cells to a TH2 phenotype46–48. Kca3.1 can thus affect T cell activation by maintaining a 
negative membrane potential and continuing Ca2+ release via CRAC channels31.
ERICH1, which encodes the glutamate rich 1 protein, was found to be differentially methylated in 4 out of 5 
low and high cytokine groups. Glutamate is an excitory neurotransmitter of the nervous system, which is critical 
for brain development and function and plays a signalling role in peripheral organs, including T lymphocytes32,49. 
It can be produced by several cells of the immune system including T cells, dendritic cells and others. Glutamate 
mediates intracellular Ca2+ fluxes and outward K+ flows thereby affecting adhesion, migration, proliferation, 
survival, activation and metabolism of T cells32,49,50. A differential methylation of ERICH1 could therefore lead to 
varied intracellular glutamate levels affecting the immune response to the BCG vaccine.
To look more broadly at differentially methylated genes, we investigated the array of pathways which con-
tained differentially methylated genes. As expected, we found several immune pathways: T cell activation, JAK/
STAT signalling, Interleukin signalling, Interferon-gamma signalling, inflammation mediated by chemokine and 
cytokine signalling, integrin signalling, TGF-beta signalling, B cell activation. All these pathways could contribute 
to the underlying differences observed in the cytokine response to the BCG vaccine. Interestingly, we also found 
a large proportion of pathways that were involved in metabolic and cellular processes. Several neurotransmitter 
mediating pathways were highlighted.
Muscarinic acetylcholine receptor signalling pathway signals via muscarinic acetylcholine receptors 
(mAChRs), which is made up of five types (M1–M5) of class A G protein-coupled receptors (GPCRs)51. Activation 
of T cells with PHA and PMA upregulates the expression of mAChRs52,53; a stimulation via CD11a upregulates M5 
gene expression52 suggesting an increase in cholinergic transmission following T cell activation; a stimulation of 
mAChRs in PBMC upregulated the IL2 production35; and M1-M5 knockout mice produced lower levels of OVA 
Specific IgG1, TNFα and IL-654.
Seven genes in the GPCRs signalling pathway were differentially methylated across low and high cytokine 
groups. G proteins act as molecular switches to control downstream effector molecules including chemokines 
and chemokine receptors33. In immune cells, G proteins impact signal transduction and affect survival, prolifera-
tion, differentiation and cell migration and recent evidence suggests non-canonical GPCR signalling in immune 
cells33,55.
The WNT pathway, of which 6 genes were differentially methylated, is known to indirectly influence the 
immune system. There are 19 WNT genes in the human genome and they all encode lipid-modified secreted 
glycoproteins. There is numerous evidence that show how the WNT proteins affect the immune system: WNT1 
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and WNT4 deficient mice have impaired T and B cell development56,57; WNT proteins are crucial for the initial 
proliferation of thymocytes before β-selection58; the overexpression of WNT signalling increases the survival of 
CD4+CD25+ regulatory T cells (Tregs)59; and WNT signalling in APCs results in increased IL12 production and 
subsequent TH1 differentiation34. Variation in methylation of WNT genes could therefore lead to changes in 
WNT proteins, ultimately leading to mediating the immune response to the BCG vaccine.
A report by Verma et al.28 has recently investigated the effect of BCG vaccination on the DNA methylation 
of PBMCs in vivo. They found an enrichment of the DNA methylation in genes of immune pathways, includ-
ing T cell activation, after the BCG vaccine vs. before vaccination. Their study shows that several non-immune 
pathways such as regulation of biological processes are enriched however these processes were not discussed in 
the report. It is important to highlight notable differences between the current study and that of Verma et al. We 
investigated the preceding methylation patterns induced by BCG vaccination and how they regulate the immune 
response to BCG stimulation in infants whereas the Verma et al. study investigated how BCG vaccination modu-
lates the DNA methylation of PBMCs in adults.
Hierarchical cluster analysis of DNA methylation revealed visible differences in cluster formation between 
high and low IFNγ groups as well as other cytokines but tSNE analysis failed to separate infants based on their 
DNA methylation patterns. These findings suggest that DNA methylation is probably not the main mechanism to 
Figure 3. A hierarchical per probe normalised clustering analysis of the DNA methylation profile between 
high and low IFNγ (A), IL2 (B), IL8 (C), IL4/5/13 (D) and TNFα (E) responder groups. First fifteen columns 
represent a methylation of probes in cytokine high responder group and last fifteen columns represent a 
methylation of probes in the low responder group. Each horizontal line represents a differentially methylated 
probe. n = 30.
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regulate the immune response to the BCG vaccine and other epigenetic mechanisms might play a role. Histone 
modifications and microRNA are other types of epigenetic modifications that could explain differences in 
observed immune responses. Histone modifications are known to control transcriptional profile of memory lym-
phocytes thereby shaping their function60. They also regulate mechanisms of adaptive features of trained immu-
nity61. microRNAs have shown to play a role in modulation of inflammatory responses62.
We acknowledge that the observed differences in DNA methylation patterns may not be specific to the BCG 
vaccine responses and may in fact, represent a regulation of general vaccine induced immune responses. However, 
it is important to highlight that in a context of this study, cytokine levels were measured after BCG stimulation, 
hence they are BCG specific. Thus, the differences in cytokine levels and the subsequent stratification to low and 
high cytokine responding groups is BCG specific. The DNA methylation differences observed between these 
groups are associated with BCG specific differences in cytokine responses, however we cannot exclude that they 
may also be associated with immune responses to other vaccines.
Taken together, the data reported here identified genes and pathways that were differentially methylated in 
PBMC from infants with high or low cytokine responses to BCG vaccination. As expected we observed a differ-
ential methylation of multiple immune pathways that could directly influence the disparate immune responses 
to the BCG vaccine. Unexpectedly, we identified several genes and pathways that could indirectly affect the BCG 
specific cytokine production. These findings suggest that in addition to immune pathways, vaccine induced 
immune responses could be modulated by molecular mechanisms and mediators that regulate cellular processes 
such as glutamate, flux of potassium and calcium through membrane channels, GPCRs and mACHRs signalling 
and the WNT pathway. Studies should focus on investigating the role of methylation as well as other epigenetic 
marks in the regulation of the genes and pathways in question as well as measuring differences in gene expression 
when stratified by high and low cytokine responses. This knowledge will allow us to understand the molecular 
mechanisms that drive vaccine-induced immune responses, paving a way to design better and more effective TB 
vaccines.
Methods
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Study participants. We retrieved blood samples collected from a subset of 10 week old infants who were 
enrolled into a large study of BCG vaccination at the South African Vaccine Initiative (SATVI) field site in the 
Name of the Biological Process
Number of Genes 
Involved
% of Total 
Genes
Biological Processes Of Differentially Methylated Genes
Cellular Process 80 25.3
Metabolic Process 66 20.8
Response To Stimulus 34 10.8
Biological Regulation 30 9.4
Developmental Process 30 9.4
Multicellular Organismal Process 25 7.8
Localization 18 5.6
Cellular Component Organization Or Biogenesis 13 4.2
Immune System Process 9 2.8
Biological Adhesion 6 1.9
Locomotion 4 1.1
Reproduction 3 0.8
Pathway Name Number of Genes Involved
% of Total 
Genes
Highlighted Pathways of Differentially Methylated Genes
Heterotrimeric G-Protein Signaling Pathway-Gi Alpha And 
Gs Alpha Mediated Pathway 7 4.2
Integrin Signaling Pathway 6 3.6
Heterotrimeric G-Protein Signaling Pathway-Gq Alpha 
And Go Alpha Mediated Pathway 6 3.6
Wnt Signalling Pathway 6 3.6
T Cell Activation 5 3.0
Inflammation Mediated By Chemokine And Cytokine 
Signaling Pathway 3 1.8
Muscarinic Acetylcholine Receptor 1 And 3 Signaling 
Pathway 3 1.8
Table 2. An overview of biological processes and selected pathways of the differentially methylated genes when 
stratified by low and high cytokine groups. Each row shows a biological process or a pathway and a number of 
differentially methylated genes associated with it.
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Worcester area, near Cape Town, South Africa (Hawkridge et al., BMJ 200818. Parents All participants were vac-
cinated with BCG at birth and samples were collected 10 weeks after birth. Participants were excluded from the 
study if any of the exclusion criteria were met: infant not immunised with BCG within 24 hours; mother infected 
with human immunodeficiency virus (HIV); chronic and acute disease in the infant at the time of enrolment; 
clinical anaemia in the infant; significant perinatal complications in the infant; and contact with any person with 
TB disease or anyone who was coughing. Participants were followed for two years to observe the development of 
TB disease. Only healthy infants who did not develop TB disease were selected for this study. Parents gave consent 
for their infants to participate in the study. The study was conducted according to the U.S. Department of Health 
and Human Services and Good Clinical Practice guidelines, and included protocol approval by the University 
of Cape Town Research Ethics Committee and written informed consent from the parent or legal guardian. The 
study also received ethical approval from the Ethics Committee of the London School of Hygiene and Tropical 
Medicine (LSHTM, #8720).
Cell separation, processing and stimulation. The methods below have been previously published in 
other studies18,63. Heparinized blood samples were collected from infants. Peripheral blood mononuclear cells 
were isolated using the density gradient centrifugation. The remaining 1 ml of blood was incubated with BCG 
(SSI, 1.2 × 106 organisms/ml), medium alone, and staphylococcal enterotoxin B (10 μg/ml; Sigma-Aldrich) (SEB). 
The co-stimulatory antibodies, anti-CD28 and anti-CD49d antibodies (1 μg/ml each; BD Biosciences, San Jose, 
CA) were added to all conditions. Samples were incubated for 7 hours at 37 °C. Later, Brefeldin-A was added and 
samples were incubated for another 5 hours. Red blood cells were lysed and white cells fixed using FACS Lysing 
Solution (BD Biosciences). Cells were collected, fixed and cryopreserved as described elsewhere63. Thus, for each 
participant non-stimulated PBMC sample and three stimulated and fixed whole blood samples were available.
Intracellular cytokine staining. Previously stimulated samples were thawed and washed in FACS buffer 
(PBS, 5% FBS v/v, 0.05% sodium azide w/v) and stained for 30 minutes at 4 °C in the dark, with a cocktail of 
surface marker antibodies: CD3-BV650 (clone SK7), CD4-BV605 (clone S3.5), CCR7-PECF594 (clone 150503), 
CD45RO-APC-H7 (clone UCHL1), (all BD Bioscience) and CD8-BV570 (clone RPA-T8; BioLegend). Samples 
were then permeabilised using the Cytoperm/Cytofix (BD Pharmingen) solution for 20 mins. After perme-
abilisation, cells were stained for 30 minutes at room temperature in the dark with a cocktail of intracellular 
cytokine antibodies: TNFα-PE-Cy7 (clone Mab11), IFNγ-V450 (clone B27), IL-2-FITC (clone MQ1-17H12), 
(BD Bioscience), IL-4-PE (clone 3010.211; FastImmune), IL-5-PE (clone TRFK5), IL-13-PE (JES10-5A2) and 
IL-8-APC (clone E8A1), (BioLegend). IL4, 5 and 13 were collected in one PE channel. After staining, samples 
were washed and stored at 4 °C in the dark to be acquired within 24 hours using BD LSRII Flow Cytometer and 
acquiring a minimum of 200,00 events.
Sample selection and DNA isolation. Samples were stratified based on the results of the ICS assay and 
the BCG specific IFNγ response. Corresponding PBMC samples of the 15 lowest (hereafter called IFNγ Low) and 
15 highest IFNγ (hereafter called IFNγ High) respondents were selected for the DNA methylation analysis. The 
selected 30 samples were later stratified based on their IL2, IL8, IL4/5/13 and TNFα responses effectively forming 
5 low and high cytokine groups. DNA was extracted using the Dneasy Blood & Tissue Kit (Qiagen). The quality 
of the DNA was checked with NanoDrop (Thermo Fisher Scientific) and the concentration measured with Qubit 
dsDNA HS Assay Kit (Thermo Fisher Scientific).
Measurement of the DNA methylation. The DNA methylation was examined using a reduced rep-
resentation bisulphite sequencing (RRBS) method and with the Premium Reduced Representation Bisulphite 
Sequencing Kit (Diagenode) according to manufacturer’s instructions.
DNA quality control and MiSeq sequencing. DNA concentration was measured using the Qubit 
dsDNA HS Assay Kit and size examined with the High Sensitivity DNA Analysis Kit (Genomics Agilent) using 
Bioanalyzer 2100 (Genomics Agilent). DNA was denatured with 0.2 M NaOH and its concentration was adjusted 
to 16pM. Samples were sequenced with the MiSeq Reagent Kit v3 (Illumina) at 51 cycles per run and single end 
reads. A 12.5 pM PhiX v3 library (Illumina) was added for a positive control.
Data processing. FASTA files were generated as the DNA sequencing output. Sequences were trimmed 
using the TrimGalore (v0.4.3) and Cutadapt software discarding all reads below 30 Phred quality score. The qual-
ity of samples was measured using the FastQC software (v0.11.5). A bisulphite treated human genome reference 
sequence was prepared using the GrCh38p7 assembly and Bismark Genome Preparation (v0.16.3) and Bowtie2 
(v2.2.9) software. Samples were mapped to the reference genome using Bismark (v0.16.3) and Bowtie2. The DNA 
methylation was extracted using Bismark Methylation Extractor (v0.16.3).
Data analysis: DNA methylation. The methylation of DNA sequences was analysed using SeqMonk 
(v1.38.2) and Rstudio (1.0.44) software. Contig methylation probes were generated with a 10-fold depth cut off, 
ignoring duplicate reads and merging probes closer that 500 bp. Probes were quantified using read count quanti-
tation and filtered to include probes measured at least 10 times. Chromosomes X, Y and any mitochondrial DNA 
were removed and probes were quantitated using bisulphite methylation pipeline embedded in the SeqMonk 
software. Based on the previous ICS responses of whole blood samples, DNA samples were then separated into 
two groups: IFNγ low & IFNγ high and a logistic regression with a P-value cut-off of 0.05 and multiple testing 
correction was run. The logistic regression test was then performed on other cytokine groups: IL4/5/13 low & 
IL4/5/13 high; IL2 low & IL2 high; TNFα low & TNFα high; and IL8 low and IL8 high. Genes that were differen-
tially methylated were visualised using SeqMonk, Panther Pathway Analysis and Cytospace (v3.5.1).
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Data analysis: correlation of immune responses. We used StataSE (v15.0) software to measure 
whether the magnitude of the BCG induced immune response is cell population dependent. Frequencies of 
BCG specific cytokines (TNFα, IFNγ, IL2, IL8 and IL4/5/13) and cell phenotypes (CD3 + CD4 + CCR7 + , 
CD3 + CD4 + CD45RO + , CD3 + , CD3 + CD4 + , CD3 + CD8 + , % of Lymphocytes) were correlated with the 
BCG specific IFNγ response using spearman correlation.
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